2020
Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update
Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers 2020, 12: 791. PMID: 32224882, PMCID: PMC7226474, DOI: 10.3390/cancers12040791.Peer-Reviewed Original ResearchStage hepatocellular carcinomaSelective internal radiotherapyAdvanced-stage hepatocellular carcinomaTrans-arterial chemoembolizationHepatocellular carcinomaRecent large prospective trialsSimilar disease control rateManagement of HCCEarly-stage hepatocellular carcinomaStage of HCCDisease control rateSystemic treatment optionsLarge prospective trialsLocal disease controlCancer-related morbidityArterial therapyProspective trialImproved tolerabilityPalliative optionControl rateTreatment optionsTherapeutic strategiesDisease controlInternal radiotherapyTolerability
2006
Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer
Murthy R, Oh Y, Tam A, Gupta S, Madoff D, Glisson B. Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Journal Of Clinical Oncology 2006, 24: 17122-17122. DOI: 10.1200/jco.2006.24.18_suppl.17122.Peer-Reviewed Original ResearchHepatic metastasesSIR-SpheresLung cancerLiver metastasesSystemic therapyAdvanced liver metastasesLiver-dominant metastasesPrimary lung malignancyRegional hepatic therapyUnresectable hepatic metastasesColorectal liver metastasesLocal disease controlMetastatic lung cancerYttrium-90 Microsphere TreatmentMajority of patientsProgression of diseaseGr. 1Dominant metastasesStable diseaseVisceral arteriographyMedian doseSystemic chemotherapyArterial embolizationLine therapyMedian interval